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intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI).
OBJECTIVES The objective of this study was to examine whether shorter LOS is safe for older patients undergoing PPCI
for STEMI.
METHODS The study analyzed patients’ characteristics and 30-day outcomes by LOS (short,#3 days; medium, 4 to 5 days; long
>5days;whereLOSwasthedischargedateminustheadmissiondateplus1)among33,920patientswithSTEMI inthe linkedCathPCI
Registry-Centers for Medicare &Medicaid Services dataset whowere$65 years of age and treated with PPCI from 2004 to 2009.
RESULTS Percents of patients in each category were as follows: 26.9%, 46.3%, and 26.8% for short, medium, and long
LOS, respectively. Patients with a long LOSwere generally older, female, and hadmore comorbidities, including cardiogenic
shock and multivessel disease. Patients with a short LOS generally had higher ejection fraction and single-vessel disease.
Therewas no signiﬁcant difference in 30-day all-causemortality (hazard ratio [HR]: 1.00; 95%conﬁdence interval [CI]: 0.74
to 1.34) ormajor adverse cardiac events (MACE) (death, readmission formyocardial infarction, unplanned revascularization:
HR: 1.03; 95%CI:0.86 to 1.25) formediumversus short LOS. Therewas a signiﬁcant increase in adjustedmortality (HR: 2.30;
95% CI: 1.72 to 3.07) and MACE (HR: 1.75; 95% CI: 1.44 to 2.12) for long versus short LOS. Patients with a very short LOS
(1 to 2 days) had signiﬁcantly increased 30-day mortality and MACE compared with a 3- to 4-day LOS.
CONCLUSIONS Patients discharged as early as 48 h after PPCI have outcomes similar to patients who stay in the
hospital for 4 to 5 days. Early, but not very early (<48 h), discharge may be safe among selected older patients with
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College
of Cardiology
AHA = American
Heart Association
CABG = coronary artery
bypass grafting
CMS = Centers for Medicare &
Medicaid Services
IABP = intra-aortic
balloon pump
ICD-9-CM = International
Classiﬁcation of Diseases-Ninth
Revision-Clinical Modiﬁcation
LAD = left anterior descending
LOS = length of stay
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous
coronary intervention
PPCI = primary percutaneous
coronary intervention
STEMI = ST-segment elevation
myocardial infarction
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1162H ospital length of stay (LOS) is acritical measure of health care efﬁ-ciency, yet it must be carefully
balanced with health care quality. Reducing
LOS is driven by ﬁnancial pressures in the
setting of decreasing reimbursements or
bundled payment models proposed by the
Centers for Medicare & Medicaid Services
(CMS) (1). In contrast, longer LOS allows for
improved patient-centered care and transi-
tion to the outpatient setting, which may
result in lowered readmission rates and
improved health outcomes (2). These issues
are particularly germane to patients present-
ing with an ST-segment elevation myocardial
infarction (STEMI), in whom in-hospital
monitoring is important to detect arrhyth-
mias and mechanical complications of myo-
cardial infarction (MI), optimize secondary
prevention, and provide education regarding
risk factor modiﬁcation, medication adher-
ence, and rehabilitation. Although primary
percutaneous coronary intervention (PPCI)
is associated with improved survival and
reduced risk of arrhythmic and mechanicalcomplications compared with ﬁbrinolytic therapy
(3–7), there remains a substantial risk for subacute
stent thrombosis and heart failure. In the current
era of PPCI, there has been a decline in LOS in
the United States after STEMI, with signiﬁcant
geographic variation in discharge practice patterns
(8). Median LOS is shortest in the United States
compared with other countries (9). Whether these
shorter hospital stays are safe remains unclear.SEE PAGE 1172In the current study, we used the linked national
CathPCI Registry with the CMS claims data to
examine LOS of older patients with STEMI and asso-
ciated 30-day clinical outcomes, including mortality
and combined major adverse cardiovascular events
(MACE: mortality, readmission for MI, or unplanned
revascularization) during the period from 2004 to
2009. We hypothesized that early discharge was as
safe as longer LOS with respect to clinical outcomes at
30 days.
METHODS
DATA COLLECTION. The CathPCI Registry, co-
sponsored by the American College of Cardiology
and the Society for Cardiovascular Angiography and
Interventions, is a large, national registry of pa-
tients undergoing diagnostic cardiac catheterizationsand/or percutaneous coronary intervention (PCI) that
captures w85% of PCI procedures performed at
>1,400 hospitals. Details of the registry, data collec-
tion, and monitoring have been previously described
(10–13). This study used version 3.0 of the CathPCI
Registry, which is the latest version linked to CMS
claims. Procedure codes were used to identify index
procedures in the Medicare ﬁles, which were then
linked to the CathPCI Registry by using indirect
identiﬁers. Linking rules were applied using a hier-
archical matching algorithm (14,15), until a match was
achieved. The feasibility of linkage to CMS claims has
been previously described (14), and it has been used
by other analyses of CathPCI data that sought long-
term outcomes (15). The Institutional Review Board
of Duke University Medical Center in Durham, North
Carolina approved the study after determining that
the study met the deﬁnition of research not requiring
informed consent.
STUDY POPULATION, DEFINITIONS, AND OUTCOME
MEASURES. We included patients who had electro-
cardiographic evidence of ST-segment elevations
on presentation to emergency departments at
acute care hospitals with PPCI capabilities and who
subsequently underwent PPCI from January 6, 2004
to December 31, 2009. We excluded the following
patients: those <65 years of age or >90 years of age
(n ¼ 1,208); STEMI transfers from centers without
PPCI capabilities; patients receiving thrombolysis
(n ¼ 1,030); patients who were discharged to
extended care, other facilities, or nursing homes (n ¼
4,297); and patients with in-hospital death (n ¼ 3,736)
or coronary artery bypass grafting (CABG) (n ¼ 1,862).
The ﬁnal study population totaled 33,920 patients
who were discharged home alive. LOS was deﬁned by
the standard CMS deﬁnition, as reported in LOS
published data (16), as the discharge date minus the
admission date plus 1. In other words, a LOS of 3 is
actually 2 days after the day of admission/PCI (e.g.
Wednesday discharge after Monday admission/PCI).
Given the discrete nature of LOS, we stratiﬁed LOS
into approximate tertiles: short (#3 days), medium
(4 to 5 days), and long (>5 days). We also separately
analyzed the group of patients with very short LOS
(1 to 2 days) relative to other LOS days.
Our primary outcomes were post-discharge 30-day
clinical events stratiﬁed by LOS, including mortality
and MACE (deﬁned as a composite of mortality,
readmission for MI, or unplanned repeat revascular-
ization). Secondary outcomes included the incidence
of 30-day readmission for MI, unplanned revascular-
ization, and bleeding events (accounting for death as
a competing factor). All-cause mortality was obtained
from the claims data. Readmissions for MI and
FIGURE 1 Study Sample Selection Flow Diagram
Length of stay ≤3 days
(n = 9,135)
Length of stay 4–5 days
(n = 15,704)
Primary Endpoints:
All-cause mortality, MACE (death, readmission
for MI, or unplanned revascularization)
Secondary Endpoints:
Readmission for MI, unplanned repeat
revascularization, bleeding
Length of stay >5 days
(n = 9,081)
Exclude if not admitted through emergency department, received
thrombolytic therapy, age <65 or >90 years, in–hospital death, in–hospital
CABG, discharge other than home, or not Fee For Service Eligible
(n = 33,920)
Patients with STEMI with admission linked to CMS
(n = 84,050)
CABG ¼ coronary artery bypass graft; CMS ¼ Centers for Medicare & Medicaid Services;
MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction; STEMI ¼ ST-segment
elevation myocardial infarction.
FIGURE 2 Distribution of LOS for the Overall Study Population
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1163unplanned revascularization that occurred during
follow-up were obtained from claims data using the
International Classiﬁcation of Diseases-Ninth Revi-
sion-Clinical Modiﬁcation (ICD-9-CM) diagnosis code
410.X1 (MI) and ICD-9-CM procedure codes 36.00,
36.06, 36.07, 36.09, and 36.10 to 36.19 (revasculari-
zation). Unplanned repeat revascularization was
deﬁned as readmission with a PCI or CABG procedure
and a principal discharge diagnosis that was clearly
not consistent with an elective readmission (17):
speciﬁcally, heart failure, acute MI, unstable angina,
arrhythmia, or cardiac arrest. Readmissions for bleed-
ing were identiﬁed from claims data using the
following ICD-9-CMdiagnosis codes: 430 to 432, 578.X,
719.1X, 423.0, 599.7, 626.2, 626.6, 626.8, 627.0, 627.1,
786.3, 784.7, or 459.0.
STATISTICAL ANALYSIS. For descriptive analyses,
baseline characteristics, procedural characteristics, in-
hospital adverse events, and hospital characteristics
were compared among patients grouped by LOS. Contin-
uous variables are presented as medians with 25th and
75thpercentiles, andcategorical variables arepresented as
frequencies (percents). Differences among patient groups
were compared using Pearson chi-square tests for cate-
gorical variables and Mann-Whitney Wilcoxon rank sum
test for continuous variables.
Estimates of the event rates for primary endpoints
at 30 days post-discharge were determined on the
basis of weights that were functions of Kaplan-Meier
censoring estimates; the log-rank test was used to
assess differences by LOS group. The cumulative
incidence differences for time-to-event clinical out-
comes were assessed using Gray’s method (18). Both
the unadjusted and adjusted hazard ratios (HRs) were
estimated for comparison of LOS groups along with a
95% conﬁdence interval (CI) on the basis of the
sandwich estimator of standard errors to account for
within-hospital correlation. The adjusted analysis
included the variables adopted in the validated
CathPCI Registry all-cause mortality model as cova-
riates, which consisted of age, race, sex, body mass
index, glomerular ﬁltration rate, presence of cardio-
genic shock at admission, medical history (i.e.,
congestive heart failure, diabetes, valvular surgery,
cerebrovascular disease, peripheral vascular disease,
chronic lung disease, dialysis, PCI), highest-risk
lesion characteristics, New York Heart Association
(NYHA) functional class, and pre-procedure intra-
aortic balloon pump (IABP), ejection fraction (19), as
well as in-hospital bleeding, vascular complications,
need for transfusions, and hospital characteristics.
To examine factors associated with longer LOS
(deﬁned as greater than the median LOS of 4 days),
a multivariable logistic regression with generalizedestimating equations was used. The generalized
estimating equations method was used to account for
within-hospital clustering (20), because patients at
the same hospital are more likely to receive similar
TABLE 1 Baseline Characteristics of Patients, Procedures, In-Hospital Adverse Events, and Hospitals*
Overall
(N ¼ 33,920)
LOS #3 days
(n ¼ 9,135)
LOS 4-5 days
(n ¼ 15,704)
LOS >5 days
(n ¼ 9,081) p Value
Patient characteristics
Age, yrs 73.0 (69.0–79.0) 72.0 (68.0–78.0) 73.0 (68.0–79.0) 76.0 (70.0–81.0) <0.001
Female 13,524 (39.87) 3,037 (33.25) 6,181 (39.36) 4,306 (47.42) <0.001
Nonwhite race 3,126 (9.21) 673 (7.37) 1,410 (8.98) 1,043 (11.48) <0.001
Prior MI (>7 days) 6,281 (18.52) 1,723 (18.86) 2,723 (17.34) 1,835 (20.21) <0.001
Prior congestive heart failure 1,950 (5.75) 332 (3.63) 703 (4.48) 915 (10.08) <0.001
Diabetes 7,869 (23.20) 1,917 (20.99) 3,470 (22.10) 2,482 (27.33) <0.001
Prior renal failure 1,359 (4.01) 248 (2.71) 497 (3.16) 614 (6.76) <0.001
Cerebrovascular disease 3,391 (10.00) 742 (8.12) 1,429 (9.10) 1,220 (13.43) <0.001
Peripheral vascular disease 3,023 (8.91) 711 (7.78) 1,270 (8.09) 1,042 (11.47) <0.001
Chronic lung disease 4,778 (14.09) 1,103 (12.07) 1,971 (12.55) 1,704 (18.76) <0.001
Hypertension 24,049 (70.90) 6,342 (69.43) 10,971 (69.86) 6,736 (74.18) <0.001
Tobacco history 15,245 (44.94) 4,194 (45.91) 7,074 (45.05) 3,977 (43.79) <0.001
Dyslipidemia 20,933 (61.71) 5,787 (63.35) 9,601 (61.14) 5,545 (61.06) <0.001
Prior PCI 7,103 (20.94) 2,072 (22.68) 3,104 (19.77) 1,927 (21.22) <0.001
Prior CABG 3,361 (9.91) 963 (10.54) 1,454 (9.26) 944 (10.40) 0.001
Congestive heart failure 3,122 (9.20) 477 (5.22) 1,118 (7.12) 1,527 (16.82) <0.001
Cardiogenic shock 2,373 (7.00) 235 (2.57) 768 (4.89) 1,370 (15.09) <0.001
Symptom onset to admission time <0.001
#6 h 27,074 (79.82) 7,391 (80.91) 12,663 (80.64) 7,020 (77.30)
>6 h and #12 h 2,947 (8.69) 738 (8.08) 1,357 (8.64) 852 (9.38)
>12 h 3,548 (10.46) 905 (9.91) 1,546 (9.84) 1,097 (12.08)
Procedure/in-hospital adverse events
Contrast volume, ml 200.0 (150.0–250.0) 185.0 (145.0–240.0) 200.0 (150.0–250.0) 200.0 (150.0–267.0) <0.001
IABP insertion 2,225 (6.56) 66 (0.72) 629 (4.01) 1,530 (16.85) <0.001
LVEF, % 47.0 (40.0–55.0) 50.0 (45.0–60.0) 48.0 (40.0–55.0) 40.0 (30.0–50.0) <0.001
Percutaneous entry location <0.001
Femoral 33,324 (98.24) 8,943 (97.90) 15,455 (98.41) 8,926 (98.29)
Radial 323 (0.95) 123 (1.35) 133 (0.85) 67 (0.74)
Multivessel disease 19,859 (58.55) 5,041 (55.18) 9,759 (62.14) 5,943 (65.44) <0.001
High-risk (type C) lesion 20,864 (61.51) 5,162 (56.51) 8,363 (61.02) 5,173 (64.72) <0.001
Bifurcation lesion 3,679 (10.85) 908 (9.94) 1,714 (10.91) 1,057 (11.64) 0.001
Culprit artery segment <0.001
Left main artery 151 (0.45) 31 (0.34) 69 (0.44) 51 (0.56)
Proximal LAD 5,773 (17.02) 1,051 (11.51) 2,570 (16.37) 2,152 (23.70)
Pre-procedure TIMI ﬂow grade <0.001
0 (no ﬂow) 20,498 (60.43) 4,784 (52.37) 9,737 (62.00) 5,977 (65.82)
1 4,417 (13.02) 1,253 (13.72) 2,034 (12.95) 1,130 (12.44)
2 4,914 (14.49) 1,609 (17.61) 2,197 (13.99) 1,108 (12.20)
3 (complete ﬂow) 3,960 (11.67) 1,455 (15.93) 1,667 (10.62) 838 (9.23)
PCI procedure success 31,320 (92.33) 8,681 (95.03) 14,648 (93.28) 7,991 (88.00) <0.001
Periprocedural MI 276 (0.81) 55 (0.60) 83 (0.53) 138 (1.52) <0.001
Cardiogenic shock 505 (1.60) 27 (0.30) 134 (0.90) 344 (4.46) <0.001
Congestive heart failure 815 (2.65) 26 (0.30) 170 (1.17) 619 (8.19) <0.001
Cerebrovascular accident/stroke 68 (0.20) 2 (0.02) 13 (0.08) 53 (0.58) <0.001
Renal failure 167 (0.51) 2 (0.02) 19 (0.12) 146 (1.72) <0.001
Any bleeding 1,918 (5.65) 128 (1.40) 633 (4.03) 1,157 (12.74) <0.001
Any vascular complication 323 (0.95) 23 (0.25) 115 (0.73) 185 (2.04) <0.001
Continued on the next page
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1164treatment relative to patients in other hospitals (i.e.,
within-center correlation for response). The adjusted
analysis included covariates from the CathPCI Regis-
try mortality model as well as in-hospital complica-
tions (i.e., bleeding, need for transfusions, vascular
complications, renal failure).To evaluate mortality and MACE rates of the very
short LOS group relative to other LOS days further, we
also performed a propensity-matched analysis to
account for differences in case mix between the very
short LOS group (LOS 1–2) and other LOS days
(LOS 3–4) more robustly. We used the “gmatch” macro
TABLE 1 Continued
Overall
(N ¼ 33,920)
LOS #3 days
(n ¼ 9,135)
LOS 4-5 days
(n ¼ 15,704)
LOS >5 days
(n ¼ 9,081) p Value
Hospital
Number of beds 390.0 (278.0–531.0) 366.0 (256.0–510.0) 394.0 (283.0–537.0) 410.0 (300.0–560.0) <0.001
University hospital 2,270 (6.69) 463 (5.07) 1,092 (6.95) 715 (7.87) <0.001
Hospital region <0.001
West 5,942 (17.52) 2,064 (22.59) 2,483 (15.81) 1,395 (15.36)
Northeast 4,373 (12.89) 705 (7.72) 2,312 (14.72) 1,356 (14.93)
Midwest 10,833 (31.94) 3,236 (35.42) 4,929 (31.39) 2,668 (29.38)
South 12,731 (37.53) 3,125 (34.21) 5,959 (37.95) 3,647 (40.16)
Number of annual PCI cases 659.90 (404.19–1,083.80) 628.65 (378.37–978.81) 663.88 (405.31–1,083.80) 700.68 (425.83–1,166.40) <0.001
Values are median (IQR) or n (%). *Baseline characteristics stratiﬁed by LOS categories.
CABG ¼ coronary artery bypass graft surgery; IABP ¼ intra-aortic balloon pump; IQR ¼ interquartile range; LAD ¼ left anterior descending; LOS ¼ length of stay; LVEF ¼ left ventricular ejection fraction;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1165from the Mayo Clinic, which performs greedy matching
of cases to control subjects (LOS 3–4 vs. LOS 1–2) within a
pre-speciﬁed caliper having a width of 0.2 times the
SD of the logit of the propensity score. In the propensity
score model, we adjusted for the variables in the NCDR
mortality model, hospital characteristics, and additional
patient and procedural factors including in-hospital
complications of bleeding, transfusions, vascular com-
plications, and renal insufﬁciency. To estimate the LOS
3–4 versus LOS 1–2 effect on outcomes among the pro-
pensity matched sample, we present the odds ratio (OR)
from a logistic regression model stratiﬁed by matched
pair. We were able to match 85% of the patients with
a very short LOS within the pre-speciﬁed caliper for
analysis.
To assess LOS trends over time, we calculated
percentiles of the distribution of LOS by discharge
year. A p value <0.05 was considered signiﬁcant for
all tests. The Duke Clinical Research Institute per-
formed all statistical analyses using SAS software
version 9.2 (SAS Institute, Cary, North Carolina).
RESULTS
BASELINE CHARACTERISTICS BY LOS. During the
study period, 33,920 patients with STEMI pre-
sented to 1,028 sites after inclusion and exclusion
criteria were applied to the linked dataset, where
the matching algorithm successfully linked 70% of
eligible patients (Figure 1). The distribution of LOS is
displayed in Figure 2, and the proportion of patients
in each LOS category was as follows: short LOS
(26.9%, n ¼ 9,135), medium LOS (46.3%, n ¼ 15,704),
and long LOS (26.8%, n ¼ 9,081).
There were differences in baseline demographics
among the 3 examined groups, with short and
medium LOS groups having fewer comorbidities
compared with the long LOS group (Table 1). Overall,patients with longer LOS were older and more
frequently had prior MI, heart failure, diabetes, renal
failure, cerebrovascular disease, peripheral vascular
disease, chronic lung disease, hypertension, and
shock. In addition, symptom onset to admission time
was generally shorter in short and medium LOS
groups (18.0% and 18.5%, respectively) compared
with the long LOS group, in which presentation >6 h
from symptom onset was more frequent (21.5%).
There were also differences in procedural characteris-
tics and in-hospital adverse events. Patients in the short
LOS group were more likely to have preserved left ven-
tricular function (median ejection fraction 50%), non–left
anterior descending (LAD) culprit vessel, TIMI (Throm-
bolysis In Myocardial Infarction) ﬂow grade 1 to 3 before
PCI, and were more likely to have a successful PCI proce-
dure. Patients in the long LOS group hadmoremultiorgan
derangements and anatomic features associated with
worse outcomes, such as the following: multivessel dis-
ease, complex (type C) coronary lesions, LAD culprit
vessel, TIMIﬂowgrade0beforePCI, shock orheart failure,
IABP placement, and in-hospital bleeding or vascular
complications.
HOSPITAL, GEOGRAPHIC VARIATION, AND TRENDS
IN LOS. Patients in the short LOS group were more
likely to be treated at smaller hospitals with fewer
beds and annual PCI cases. Discharging patients
with STEMI early was also more commonly prac-
ticed in hospitals in the West and Midwest regions
compared with the South and Northeast (Table 1).
The median LOS over the 6-year period was
4 days; however, the relative frequency of patients
in each LOS category changed with a trend toward
earlier discharges over time. In 2005, 24% of
discharges in older patients with STEMI were in
patients with a short LOS; this percent increased
to 30% by 2009. Conversely, 47% and 29% of
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1166discharges in patients with STEMI were in patients
with medium and long LOS, respectively, and
these percents decreased to 45% and 25% by 2009,
respectively.
PRIMARY OUTCOMES. The 30-day mortality and
MACE rates were 0.9% and 1.9% for short LOS, 1.0%
and 2.2% for medium LOS, and 3.5% and 5.0% for long
LOS, respectively (p < 0.0001) (Figures 3A and 3B). A
multivariable Cox regression analysis (Table 2)
demonstrated similar adjusted rates of death andFIGURE 3 Cumulative Incidence of Primary and Secondary Outcome
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SECONDARY OUTCOMES. The incidence of read-
missions for MI at 30 days was 1.0% for short LOS
and 1.1% for medium LOS, but it was signiﬁcantly
higher at 1.6% for long LOS (p ¼ 0.001) (Figure 3C).
The rates of 30-day readmissions for unplanned
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TABLE 2 Association of LOS on Time-to-Event Within 30 Days*
Outcome LOS
Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI) p Value
Death 4–5 days vs. #3 days 1.16 (0.87–1.55) 0.32 1.00 (0.74–1.34) 0.98
>5 days vs. #3 days 3.98 (3.08–5.15) <0.001 2.30 (1.72–3.07) <0.001
MACE 4–5 days vs. #3 days 1.16 (0.96–1.40) 0.12 1.03 (0.86–1.25) 0.73
>5 days vs. #3 days 2.65 (2.22–3.15) <0.001 1.75 (1.44–2.12) <0.001
*Unadjusted and adjusted hazard ratios for death and MACE between medium versus short LOS and long versus
short LOS.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LOS ¼ length of stay; MACE ¼ major adverse cardiac event(s).
TABLE 3 Association of Selected Covariates on LOS*
LOS >4 Days vs. #3 Days
OR (95% CI) p Value
Vascular complication 3.88 (2.88–5.22) <0.001
Bleeding complication 2.61 (2.30–2.95) <0.001
Transfusion 3.94 (2.24–8.35) <0.001
Pre-operative IABP 4.32 (3.47–4.47) <0.001
Cardiogenic shock 3.01 (2.73–3.32) < 0.001
Highest-risk lesion
Proximal LAD vs. other 1.58 (1.48–1.69) <0.001
Left main vs. other 2.23 (1.55–3.23) <0.001
Renal insufﬁciency 2.68 (2.15–3.34) <0.001
Pre-procedure TIMI ﬂow grade 0 1.21 (1.14–1.29) <0.001
Age (per 10-year increase) 1.46 (1.41–1.51) <0.001
Cerebrovascular disease 1.28 (1.18–1.39) <0.001
Prior congestive heart failure 1.50 (1.34–1.67) <0.001
Peripheral vascular disease 1.07 (0.98–1.17) 0.11
Number of hospital beds
(per 100 increase)
1.06 (1.03–1.09) <0.001
Chronic lung disease 1.37 (1.28–1.47) <0.001
University hospital 0.93 (0.78–1.11) 0.41
Prior PCI 0.86 (0.82–0.91) <0.001
White race 0.83 (0.77–0.89) <0.001
Male 0.76 (0.73–0.80) <0.001
No diabetes vs. IDDM 0.61 (0.55–0.68) <0.001
Region
West vs. South 0.76 (0.67–0.86) <0.001
Northeast vs. South 1.29 (1.12–1.50) <0.001
Midwest vs. South 0.72 (0.65–0.80) <0.001
*ORs of factors associated with prolonged LOS versus short LOS.
IDDM ¼ insulin-dependent diabetes mellitus; OR ¼ odds ratio; other
abbreviations as in Tables 1 and 2.
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11671.0% for both medium and long LOS; p ¼ 0.23)
(Figure 3D). The frequency of bleeding events
requiring readmission after initial discharge was
relatively low, but it increased across all LOS cate-
gories: 0.2%, 0.4%, and 0.6% for short, medium, and
long LOS, respectively (p < 0.001) (Figure 3E).
FACTORS ASSOCIATED WITH LONGER LOS. Table 3
displays independent predictors of longer LOS
(>4 days) after controlling for baseline characteris-
tics, variables from the NCDR mortality model, and
in-hospital complications. The factors associated with
longer LOS included pre-operative IABP, transfusion,
vascular complication, cardiogenic shock, renal in-
sufﬁciency, and bleeding. Hospitals located in the
West and Midwest regions were 24% and 28% more
likely to have short versus longer LOS than hospitals
located in the South, respectively, whereas hospitals
in the Northeast had longer LOS versus hospitals in
the South (see Table 3).
VERY SHORT LOS AND OUTCOMES. Very short LOS
(1 to 2 days), which represents discharge on the day
of PCI or the day after PCI (similar to the practice for
elective PCIs) was infrequent and present in 1,244
patients (3.7%). The relationship between distribu-
tion of LOS and clinical outcomes (MACE) is shown in
Figure 4 and reveals that very short LOS is associated
with signiﬁcantly worse 30-day clinical outcomes. A
“U-shaped” curve for MACE events was noted with a
nadir at LOS 3–4, where overall unadjusted 30-day
MACE rates were similar for LOS of 3 or 4 days.
Compared with LOS 3–4 (Online Table 1), patients in
the very short LOS group were of similar age, but
more commonly they were male with hypertension,
hyperlipidemia, chronic lung disease, diabetes, and
earlier PCI or CABG. Patients in the very short
LOS group were more likely to have TIMI ﬂow grade
1 to 3 pre-PCI and a lower frequency of LAD culprits,
cardiogenic shock, any bleeding, or vascular compli-
cations. The PCI procedural success rate was similar.
Guideline-directed post-STEMI discharge medica-
tions including antiplatelet agents, beta-blockers,
and statins were less frequently prescribed in pa-
tients in the very short LOS group. Compared with
very short LOS, patients with a 3- to 4-day LOS had
>50% reduction in adjusted mortality (OR: 0.47;
95% CI: 0.27 to -0.82 for LOS 3 vs. LOS 1–2; OR:
0.46; 95% CI: 0.27 to 0.79, for LOS 4 vs. LOS 1–2)
and a more than 40% reduction in MACE (OR:
0.59; 95% CI: 0.40 to 0.86 for LOS 3 vs. LOS 1–2;
OR: 0.56; 95% CI: 0.38 to 0.82 for LOS 4 vs. LOS
1–2) (Table 4). Similarly, among propensity-matched
cohorts, the risk of death (OR: 0.41; 95% CI: 0.21 to
0.81) and MACE (OR: 0.52; 95% CI: 0.33 to 0.80)remained signiﬁcantly lower for LOS 3–4 versus
LOS 1–2.
DISCUSSION
In this large, contemporary national registry, we
found that a majority of older patients with STEMI
(46%) had a medium LOS, whereas 27% of patients
had a short LOS. After adjustment, patients with
short LOS had similar mortality and MACE rates as
those with medium LOS. These data suggest that
FIGURE 4 Association of 30-Day MACE by Each LOS Day and
Frequency of Distribution of LOS
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TABLE 4 Association
Outcome
Length of
(Days)
Death 3 vs. 1–
4 vs. 1–
5 vs. 1–
$6 vs. 1
MACE 3 vs. 1–
4 vs. 1–
5 vs. 1–
$6 vs. 1
*Unadjusted and adjusted
Abbreviations as in Tabl
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1168selected patients with STEMIwho do not develop post-
procedural complications may be eligible for an ear-
lier discharge without an increase in 30-day adverse
events (Central Illustration). Furthermore, from 2004
to 2009, the proportion of patients undergoing ear-
lier discharges increased. This pattern may reﬂect
the increasing safety of PCI in general (21), the use of
bleeding avoidance strategies (22), and the ﬁnancial
pressures for hospitals to reduce inpatient LOS.
In contrast to established guidelines for “door-to-
balloon” times, current guidelines do not provide
criteria for determining an optimal LOS or “balloon-
to-door” time for patients with STEMI. Large-scale
changes in the way post-STEMI care is delivered andof Each LOS Day on Time-to-Event Within 30-Days*
Stay Unadjusted HR
(95% CI) p Value
Adjusted HR
(95% CI) p Value
2 0.49 (0.28–0.84) 0.01 0.47 (0.27–0.82) 0.01
2 0.51 (0.30–0.87) 0.01 0.46 (0.27–0.79) <0.01
2 0.88 (0.52–1.50) 0.63 0.67 (0.39–1.15) 0.14
–2 2.21 (1.35–3.61) <0.01 1.26 (0.75–2.10) 0.38
2 0.60 (0.41–0.88) 0.01 0.59 (0.40–0.86) 0.01
2 0.61 (0.41–0.89) 0.01 0.56 (0.38–0.82) <0.01
2 1.01 (0.70–1.46) 0.96 0.82 (0.57–1.20) 0.30
–2 1.72 (1.22–2.43) <0.01 1.13 (0.79–1.61) 0.50
hazard ratios for death and MACE between each LOS day and very short LOS.
e 2.reductions in LOS nationally may be accompanied by
unintended consequences (23). Therefore, it is critical
to examine the safety and understand the effects of
such changes, particularly among Medicare beneﬁ-
ciaries with substantial comorbidities. It is reassuring
that in broadly representative older patients at more
than 1,000 centers in the United States, 30-day mor-
tality and MACE outcomes were similarly low among
patients with short and medium LOS. It remains un-
known whether shorter LOS and reduced hospital
costs align with effects on care continuity and pa-
tients’ preferences.
We found that patients with long LOS (27%) had
the highest rate of 30-day mortality and MACE. Given
the observational nature of our study, these data
should not be interpreted to mean that keeping a
patient with STEMI in the hospital beyond 5 days
would translate into poor outcomes. Rather, this
group was a sicker cohort of patients with substantial
comorbidities and in-hospital complications relative
to those with short and medium LOS, and thus these
patients would be expected to have more read-
missions within 30 days. An early discharge strategy
would apply only to patients who do not develop
post-procedural complications, and recuperation at
home would attenuate nosocomial infection and
delirium, to which older patients are prone.
Patients with short LOS had less complicated pre-
sentations. The safety of early discharge for such pa-
tients is in line with previous prospective studies
(24,25), which were limited by small sizes and
single-center experiences. The PAMI-II (Primary An-
gioplasty in Myocardial Infarction -11) study from 1998
implemented a strategy of early identiﬁcation of low-
risk patients with STEMI to receive accelerated care
in a non–intensive care unit setting with hospital
discharge on day 3 without noninvasive testing or
traditional care (24). The study showed that the ac-
celerated group had similar in-hospital and 6-month
outcomes, yet these patients were discharged 3 days
earlier than the traditional group (4.2  2.3 days vs.
7.1  4.7 days; p ¼ 0.0001). Similarly, the Safe-Depart
trial (25), a small, single-center study, identiﬁed 54
low-risk patients with STEMI on the basis of the
Zwolle Primary PCI Index (26), after these patients
underwent primary or rescue PCI, and found that an
early discharge strategy with rapid follow-up was
feasible.
An important ﬁnding of our study is that very early
discharge (same-day or overnight stay after PCI) is
associated with an increase in 30-day mortality and
MACE. Risks associated with PCI, such as acute stent
thrombosis, bleeding, and renal failure, are highest
within the ﬁrst 24 to 48 h (27); thus, longer observation
CENTRAL ILLUSTRATION Hospital LOS and Clinical Outcomes in Older Patients With STEMI After Primary PCI
Very early discharge
(same-day or
overnight
stay after PCI)
Short 
(≤3 days after PCI)
Medium
(4-5 days after PCI)
Long
(>5 days after PCI)
None
HOSPITAL LENGTH
OF STAY POST PCI TYPICAL PATIENT
EXPECTED PRIMARY OUTCOME
(30-day mortality and MACE rates)
EXPECTED SECONDARY OUTCOME
(Incidence of 30-day readmission)
High 30-day mortality and
major adverse cardiac events (MACE).
Risks associated with PCI, such as 
acute stent thrombosis, bleeding, and 
renal failure, are highest within the 
first 24 to 48 hours 
N/A
0.9% and 1.9%
1.0% and 2.2%
Similar rates as short suggesting
that patients who do not develop 
post-procedural complications may
be eligible for an earlier discharge 
without an increase in 30-day
adverse events
3.5% and 5.0%
This should not be interpreted to mean 
that keeping a patient with STEMI in 
the hospital beyond 5 days would 
translate into poor outcomes; this 
group is a sicker cohort of patients
• Myocardial infarction: 1%
• Unplanned revascularizations: 0.7%
• Bleeding event: 0.2%
• Myocardial infarction: 1.1%
• Unplanned revascularizations: 1%
• Bleeding event: 0.4%
• Myocardial infarction: 1.6%
• Unplanned revascularizations: 1%
• Bleeding event: 0.6%
• Symptom onset to admission time ≤6 hours 
• Preserved LV function prior to PCI
• Without comorbidities
• Without post-procedural complications
• Patients tend to be younger
Similar to Short
• Symptom onset to admission time >6 hours 
• Without preserved LV function prior to PCI
• With comorbidities
• With post-procedural complications
• Patients tend to be older
Swaminathan, R.V. et al. J Am Coll Cardiol. 2015; 65(12):1161–71.
A summary of 30-day mortality and major adverse cardiac events (MACE) rates stratiﬁed by length of stay (LOS) categories. LV ¼ left ventricular; PCI ¼ percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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Furthermore, optimal post-MI medications were less
frequently prescribed on discharge in patients with
very short hospital stays. The current data highlight
the importance of implementing standardized pro-
tocols for STEMI discharge and post-discharge follow-
up in patients with very short LOS, in addition to the
need for further clinical evidence that a very early
discharge strategy can be safely applied in contempo-
rary practice. From a hospital policy standpoint, this
ﬁnding supports justiﬁcation for “inpatient” moni-
toring and reimbursement under the recently intro-
duced CMS “2-midnight rule.” The concept and safety
of an “outpatient STEMI PCI” when the patient stays
<2-midnights would require further investigation and
policy discussion because clearly there would be a
disconnect between the level of monitoring required
and the time spent in the hospital.
We also found geographic and hospital-level vari-
ation that affected LOS. Hospitals with smallernumbers of beds had greater proportion of patients in
the short LOS group, a ﬁnding that may reﬂect pres-
sure to expedite bed availability. Of interest, hospi-
tals in the West and Midwest had signiﬁcantly shorter
LOS compared with the Northeast and South. Such
variation has been seen in earlier studies for STEMI
(8) and elective PCI (28), and it may be a reﬂection of
hospital discharge policy or institutional culture,
unrelated to medical or logistical factors. This ﬁnding
highlights potential areas for improvement and cost
savings within certain regions.
STUDY LIMITATIONS. First, because the CathPCI regis-
try accounts for only in-hospital events, we linked
the database to CMS claims data to obtain 30-day
clinical outcomes. This limited our population to pa-
tients older than 65 years and subjects the data to
coding bias and possibly missing events. However,
older patients are at higher risk for in-hospital com-
plications after PPCI (29–31), so it is likely that a
higher proportion of younger patients would be
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE:
The importance of in-hospital monitoring for patients
with MI and appropriate reasons for variation from the
mean 4- to 5-day inpatient stay on the basis of risk
factors and comorbidities should be made clear to
patients, family members, other caregivers, and
payers. Earlier discharge (still no <48 h after PCI)
may be safe in selected older patients undergoing
uncomplicated primary PCI.
TRANSLATIONAL OUTLOOK: Early discharge
strategies could be developed that promote safe
transitions to the outpatient setting, optimize efﬁ-
ciency, and enhance patient-oriented outcomes.
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1170eligible for earlier discharge. Second, our study
period ended in 2009, after which further evolution
in care models for patients with STEMI, advances in
bleeding avoidance strategies including increased use
of radial access for STEMI (32), and use of newer-
generation drug-eluting stents may have led to
continued reductions in LOS with a positive impact
on 30-day outcomes. Third, although our robust sta-
tistical approach using validated risk models and
propensity matching accounted for some of the po-
tential bias inherent to observational analyses, there
remains risk of unmeasured confounders. Fourth,
some patients after STEMI may return to the hospital
within 30 days for elective or “staged” revasculariza-
tion of a nonculprit artery. To minimize counting this
as an unplanned revascularization, we deﬁned repeat
revascularization as readmissions with PCI or CABG
that were associated with a principal discharge
diagnosis that was clearly not consistent with an
elective readmission. This methodology has inherent
limitations because it is based on administrative
data; however, it is currently the most reliable al-
gorithm available and has been utilized in other
published registry data. For this reason, we also
analyzed each component of the combined MACE
separately as secondary endpoints. Furthermore,
miscoding the second admission, given that it is
linked so closely to the index admission for STEMI,
may have increased readmission event rates; how-
ever, miscoding would likely be similar across the
various LOS categories. Finally, we could not ac-
count for patients who may have very short stays as
a result of leaving against medical advice, a factor
that may also portend worse outcomes secondary to
medication noncompliance. These factors, in combi-
nation with the overall small sample size of the very
short LOS group, preclude any deﬁnitive conclusions
about the potential safety of a very early discharge
strategy. Our analysis therefore raises an importantquestion that needs to be addressed in future
studies, particularly those that use chart reviews to
examine why certain patients have a very short
hospital LOS after STEMI.
CONCLUSIONS
Nearly one-half of the older patients with STEMI in
the United States who are undergoing PPCI have a 4-
to 5-day LOS, yet patients discharged earlier have
similar 30-day mortality and MACE. These data sug-
gest that early discharge (but not within 48 h after
PPCI) may be safe among selected older patients un-
dergoing PPCI for STEMI who do not develop in-
hospital complications.
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